Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials

USFDA Oncology Drug Approvals from 2014- 2025: Comparing non-immunotherapy and immunotherapy approvals, their endpoints, and their efficacy.
N. Bapodra, K. G. Morse, S. E. Bates +1
medRxiv21 Oct 2026PreprintCC BY-NDFull textOncologymedRxiv
Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis
Joshua S. Woodworth, Claus Aagaard, Francisco J. Salguero +4
NPJ Vaccines8 Jul 2026Peer-reviewedCC BY-NC-ND 4.0Full textInfectious diseasePMC
Epitope Mapping and MHC Restriction of Next-Generation Tuberculosis Vaccine Antigens in Mice.
Samuel J Vidal, Alejandro A Espinosa Perez, Ganad D Neka +11
Vaccines1 Oct 2026Peer-reviewedCC BYFull textInfectious diseaseEurope PMC
Can identifying recent Mycobacterium tuberculosis infection support faster tuberculosis vaccine trials?
L. Hadley, T. S. Brown, K. Nelson +1
medRxiv19 Oct 2026PreprintCC BYFull textInfectious diseasemedRxiv
A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older
Christy A. Comeaux, Marco Testa, Efi Gymnopoulou +15
eBioMedicine1 Nov 2026Peer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeX

@article{ruhwald2026symptomagnostic,
  title = {{Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials}},
  author = {Morten Ruhwald and Alemnew F Dagnew and Gavin Churchyard and Adam Penn-Nicholson and Puneet Dewan and Alberto L Garcia-Basteiro and Emily B Wong and Willem A Hanekom and Mark Hatherill and Reinout van Crevel and Saskia den Boon and Patricia Hall-Eidson and Rein M G J Houben and Ann M Ginsberg and Frank Cobelens and Katherine C Horton and Richard G White},
  journal = {The Lancet Global Health},
  year = {2026},
  month = oct,
  doi = {10.1016/j.langlo.2026.104079},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S2214109X2600241X},
  note = {CC BY 3.0-IGO},
}

RIS

TY  - JOUR
TI  - Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials
AU  - Morten Ruhwald
AU  - Alemnew F Dagnew
AU  - Gavin Churchyard
AU  - Adam Penn-Nicholson
AU  - Puneet Dewan
AU  - Alberto L Garcia-Basteiro
AU  - Emily B Wong
AU  - Willem A Hanekom
AU  - Mark Hatherill
AU  - Reinout van Crevel
AU  - Saskia den Boon
AU  - Patricia Hall-Eidson
AU  - Rein M G J Houben
AU  - Ann M Ginsberg
AU  - Frank Cobelens
AU  - Katherine C Horton
AU  - Richard G White
PY  - 2026
DA  - 2026/10/01
JO  - The Lancet Global Health
DO  - 10.1016/j.langlo.2026.104079
UR  - https://linkinghub.elsevier.com/retrieve/pii/S2214109X2600241X
SN  - 2214-109X
ER  -

Related

Cite